
- Oncology NEWS International Vol 5 No 5
- Volume 5
- Issue 5
DaunoXome Cleared For Kaposi's Sarcoma
BOULDER, Colorado--NeXstar Pharmaceutical's DaunoXome (dauno-rubicin citrate liposome injection) has received FDA approval for use as primary therapy for advanced HIV-associated Kaposi's sarcoma (KS).
BOULDER, Colorado--NeXstar Pharmaceutical's DaunoXome (dauno-rubicincitrate liposome injection) has received FDA approval for useas primary therapy for advanced HIV-associated Kaposi's sarcoma(KS).
In the company-sponsored phase III trial, conducted at 13 US andCanadian centers and involving 227 patients with advanced HIV-associatedKS, Dauno-Xome was found to have efficacy comparable to the three-drugregimen of Adria-mycin, bleomycin, and vincristine (ABV).
Average survival was 342 days for patients on DaunoXome vs 291days for those on ABV. Side effects such as neu-ropathy and alopeciawere reduced significantly with use of DaunoXome.
Articles in this issue
over 29 years ago
No Need to Delay Mammography After FNA, Study Showsover 29 years ago
Pediatric Cancer Guidelines Are a National Effortover 29 years ago
ATL's HDI Digital Ultrasound Is Approved for Breast Indicationover 29 years ago
Natural History of HIV Supports the Use Of Early Interventionsover 29 years ago
Aids Vaccine Trial Fails to Show Clinical Benefitover 29 years ago
Rep. Porter Honored For Work on BudgetNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.